Brodalumab for Moderate-to-Severe Psoriasis: A Comprehensive…
Emerging
4
Citations41
Refs2025
Year
Search Works
Work Details
- DOI 10.2147/btt.s532526
- PMID https://pubmed.ncbi.nlm.nih.gov/40688593
- PMCID https://www.ncbi.nlm.nih.gov/pmc/articles/12275985
- OpenAlex ID W4412395762
- Type Review
- Language EN
- Published 01 Jul 2025
- Volume Volume 19
- Pages 415–422
- Source Biologics
- Publisher Dove Medical Press
- FWCI 0.36
- Countries 1
- Institutions 5
- Added 10 Oct 2025
- Updated 31 Oct 2026
External Links
MENU
0
Brodalumab for Moderate-to-Severe Psoriasis: A Comprehensive Review of Efficacy, Safety, and Clinical Positioning
Review 2025 EN Gold
Brodalumab is a monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), offering a novel approach to treating moderate-to-severe psoriasis. By blocking IL-17RA, brodalumab inhibits the activity of multiple pro-inflammatory IL-17 isoforms, including IL-17A, IL-17F, and IL-17C, which are critical in the pathogenesis of psoriasis. This review synthesizes data from Phase I-IV clinical tr…
4
Citations
41
References
6
Authors
0.36
FWCI
Citations by Year
Last 1 yearsTopics
Keywords
UN Sustainable Development Goals
1 SDGsAuthors & Affiliations
6 authors| # | Author | Institutions | ORCID |
|---|---|---|---|
| 1 | Nickoulet Babaei | Loma Linda University (US) | — |
| 2 | Minka Gill | Indiana University School of M… (US) | |
| 3 | Mireya Cervantes | Albany Medical College (US) | |
| 4 | Dahyeon Kim | Loma Linda University (US) | |
| 5 | Seanna Yang | Tulane University (US) | |
| 6 | Jashin J. Wu Corresponding | University of Miami (US) |
Related Works
10Data: OpenAlex